Source: Contract Pharma

Dragonfly: Dragonfly, Merck Partner to Evaluate DF9001 in Combination with Keytruda

Hope to drive potent anti-tumor activity in a broad range of indications.

Read full article »
Dragonfly's Competitors | Dragonfly's News | Dragonfly's Financials
Stay up-to-date with the latest news on Dragonfly
Est. Annual Revenue
$100K-5.0M
Est. Employees
100-250
William Haney's photo - Co-Founder & CEO of Dragonfly

Co-Founder & CEO

William Haney

CEO Approval Rating

90/100

Read more
Stay up-to-date with the latest news on Dragonfly